Prince Anand, MD
Nephrology · Danville, PANPI 1437310968
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Calliditas Therapeutics US Inc. at 47.4% of the total. 2025 is the largest year on record at $142,883, more than ten times the $204 reported in 2019. Among nephrology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 345 payments — averaging $960.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Calliditas Therapeutics US Inc.$157K
- Veloxis Pharmaceuticals, Inc.$68K
- Apellis Pharmaceuticals, Inc.$62K
- Sanofi-aventis U.S. LLC$38K
- Novo Nordisk$4K
- Novartis$332
- plus $937 from 10 others
What the payments were for
- Consulting fees$65,63920%
- Speaking & faculty fees$198,17160%
- Travel & lodging$58,78518%
- Food & beverage$8,4473%
- Education$1440%
- Entertainment$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Calliditas Therapeutics US Inc. | 162 | $157,011 |
| Veloxis Pharmaceuticals, Inc. | 91 | $68,190 |
| Apellis Pharmaceuticals, Inc. | 40 | $62,164 |
| Sanofi-aventis U.S. LLC | 25 | $38,133 |
| Novo Nordisk | 4 | $4,440 |
| Novartis | 2 | $332 |
| AstraZeneca | 4 | $304 |
| Mallinckrodt Hospital Products Inc. | 5 | $189 |
| Sanofi | 2 | $143 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $103 |
| Otsuka America Pharmaceutical, Inc. | 1 | $61 |
| Travere Therapeutics, Inc. | 2 | $50 |
| Exact Sciences | 1 | $30 |
| Johnson & Johnson | 1 | $21 |
| Eurofins Viracor, LLC | 1 | $20 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$331,207 in reported general payments places this provider in the 95th percentile of 586 nephrology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 53 | $1,618,667 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 19 | $362,070 |
| PrevymisLetermovir | 11 | $71,346 |
| OzempicSemaglutide | 48 | $51,172 |
| JardianceEmpagliflozin | 26 | $40,205 |
| Envarsus XrTacrolimus | 37 | $36,304 |
| Cinacalcet Hcl | 82 | $22,784 |
| MounjaroTirzepatide | 16 | $22,569 |
| Valganciclovir Hcl | 84 | $19,707 |
| Atovaquone | 21 | $18,929 |
| EliquisApixaban | 16 | $12,468 |
| VeltassaPatiromer Calcium Sorbitex | 16 | $9,722 |
| Tacrolimus | 26 | $7,694 |
| Mycophenolic AcidMycophenolate Sodium | 22 | $5,247 |
| Novolog FlexpenInsulin Aspart | 26 | $3,575 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $103 | $362,07019 claims |
| MerckPrevymis | $14 | $71,34611 claims |
| Novo NordiskOzempic | $4,440 | $51,17248 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 586 nephrology providers in Pennsylvania.
Other nephrology in Danville
- Kartik KalraDanville$108K
- Alexander ChangDanville$17K
- Jason GeorgeDanville$15K
- Evan NorfolkDanville$9K
- Nelson KopytAllentown$949K
- Christopher GislerPittsburgh$757K
- Rakesh GulatiPhiladelphia$657K
- Raymond TownsendPhiladelphia$357K
- Ellie KelepourisPhiladelphia$287K
- Jonathan DiamondHarrisburg$249K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.